Venus Medtech (Hangzhou) Inc.
Venus Medtech (Hangzhou) Inc.
Your view on VMTHF
Overview
What the company does, where it operates, and who runs it.
About Venus Medtech (Hangzhou) Inc.
- Industry
- Medical - Specialties
- Sector
- Healthcare
- CEO
- Hou-Sen Lim MEng.
- Headquarters
- No. 88, Jiangling Road, Hangzhou, CN
- Industry
- Medical - Specialties
- Sector
- Healthcare
- CEO
- Hou-Sen Lim MEng.
- Headquarters
- No. 88, Jiangling Road, Hangzhou, CN
Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally.
The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries.
It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; and transcatheter mitral and tricuspid valve replacement products; Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy; and renal denervation for the treatment of hypertension.
The company was founded in 2009 and is headquartered in Hangzhou, the People's Republic of China.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Venus Medtech (Hangzhou) Inc., and the rating behind it. VMTHF last traded at $0.42; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Venus Medtech (Hangzhou) Inc.. Starting points for Venus Medtech (Hangzhou) Inc.: EPS -$1.06, beta 1.11 — an Medical - Specialties name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Venus Medtech (Hangzhou) Inc.. Venus Medtech (Hangzhou) Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Venus Medtech (Hangzhou) Inc.. Trailing twelve-month EPS for Venus Medtech (Hangzhou) Inc. stands at -$1.06. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Venus Medtech (Hangzhou) Inc.. Venus Medtech (Hangzhou) Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Venus Medtech (Hangzhou) Inc. valued side by side against its closest peers. Venus Medtech (Hangzhou) Inc. is measured against Medical - Specialties peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Venus Medtech (Hangzhou) Inc., and how their positions are changing. At a $184.7M market value, institutional positions materially move Venus Medtech (Hangzhou) Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Venus Medtech (Hangzhou) Inc. executives and directors. Shares of Venus Medtech (Hangzhou) Inc. have traded between $0.01 and $0.52 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Venus Medtech (Hangzhou) Inc.. Venus Medtech (Hangzhou) Inc. is a $184.7M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Venus Medtech (Hangzhou) Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Venus Medtech (Hangzhou) Inc.. Coverage tracks Venus Medtech (Hangzhou) Inc. within Medical - Specialties (Healthcare). Press releases and market coverage, newest first.